The improved prognosis of <i>FLT3</i>-internal tandem duplication but not tyrosine kinase domain mutations in acute myeloid leukemia in the era of targeted therapy: a real-world study using large-scale electronic health record data
Not available.
Saved in:
| Main Authors: | Matthew Schwede, Gladys Rodriguez, Vanessa E. Kennedy, Solomon Henry, Douglas Wood, Gabriel N. Mannis, Ravindra Majeti, Jonathan H. Chen, Eran Bendavid, Tian Yi Zhang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ferrata Storti Foundation
2025-02-01
|
| Series: | Haematologica |
| Online Access: | https://haematologica.org/article/view/11934 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A phase II study of ponatinib for prevention of relapse after allotransplantation in <i>FLT3</i> internal tandem duplication mutation positive (FLT3-ITD+) acute myeloid leukemia: the PONALLO trial
by: Patrice Chevallier, et al.
Published: (2025-04-01) -
FLT3 tyrosine kinase in acute non-lymphoblastic leukemias
by: A. S. Bavykin, et al.
Published: (2022-11-01) -
Concentration‐QTcF analysis of quizartinib in patients with newly diagnosed FLT3‐internal‐tandem‐duplication‐positive acute myeloid leukemia
by: Pavan Vaddady, et al.
Published: (2024-11-01) -
A novel TRKB-activating internal tandem duplication characterizes a new mechanism of receptor tyrosine kinase activation
by: Lauren M. Brown, et al.
Published: (2025-05-01) -
Neurotrophin-3 and FLT3 Tyrosine Kinase Receptor in Perinatal Life
by: Ariadne Malamitsi-Puchner, et al.
Published: (2005-01-01)